Tag: glioblastoma
-
Announcing our research partnership investment with CRUK
Scottish scientist set to receive over £6 million from Cancer Research UK and The Brain Tumour Charity to find new ways to treat glioblastoma, one of the hardest types of cancer to treat.
-
Analysis shows Deputax-M is unsuccessful
Deputax-M failed to meet its target overall survival during an interim analysis of a phase 3 clinical trial in glioblastoma
-
Nivolumab fails to meet its target
Nivolumab, an immunotherapy drug, has been unsuccessful in improving overall survival in a phase 3 clinical trial when tested in newly diagnosed glioblastoma with unmethylated MGMT
-
New treatments for diffuse midline gliomas
A new type of drug that targets a particular protein could become the first ever treatment designed for children with diffuse midline gliomas (formerly known as DIPG)
-
Hal raises dough for research
Interviewed by our Young Ambassador, Grace Latter, Hal Cruttenden opens up about his mum’s diagnosis and why he supports the work we do
-
New drug discovered that could prevent the spread of glioblastoma cells
Researchers have discovered a new drug could potentially halt the spread of glioblastoma cells
-
Halting the ‘immortality’ mechanism in glioblastomas
A team of researchers have identified a new therapeutic target in glioblastoma cells that could halt the aggressive growth of this tumour type
-
Scientists discover a chemical that can kill glioblastoma cells
Laboratory experiments show that a synthetic chemical is able to shut off glioblastoma cells’ energy source, leading to cell death
-
Positive results from a drug treating recurrent glioblastoma
New data presented at the recent American Association of Clinical Oncology (ASCO) meeting in Chicago by Abbvie, a pharmaceutical company, provides hope for those diagnosed with a glioblastoma
-
Our interview with Dr Tom Millner: Understanding Epigenetics in Glioblastoma
The research engagement team recently visited The Blizard Institute of Cell and Molecular Science in London and met with Dr Tom Millner
-
Identifying markers to classify previously undetermined glioblastomas
A study led by researchers from Duke Cancer Institute identifies genetic markers to classify previously undetermined glioblastomas
-
A new approach to brain tumour surgery shows improved survival for individuals with high-grade gliomas
Recent clinical data reports that a new surgical approach could improve survival for individuals with difficult to access high-grade gliomas
-
IOTA Pharmaceuticals announce the creation of a Glioblastoma Drug Bank
The new bank, announced today, will support and accelerate new research into brain cancer therapy
-
Researchers discover a new target for immunotherapy
Researchers design immune cells to target a protein found on two thirds of glioblastomas, the most common and lethal primary brain tumour
-
Is anti-angiogenic therapy to treat glioblastomas a viable option?
Results of two phase 2 clinical trials testing cabozantinib suggest that anti-angiogenic therapy could be used to treat glioblastomas
-
Combination therapy could significantly improve glioblastoma survival rates
Researchers at Massachusetts General Hospital prepare to launch a phase 1 clinical trial to test the combination therapy of hydroxyurea and temozolomide (TMZ)
-
Our research update into glioblastoma, adaptive trials, and the ‘pink drink’
Our Research Engagement Manager Becky Birch, outlines developments highlighted by Tessa Jowell’s debate
-
Targeting the body’s internal clock to treat glioblastoma
Researchers have discovered that the circadian rhythm, also known as a person’s ‘internal clock’, could hold the answers to develop new therapies for glioblastoma
-
Wearing an electronic cap to improve glioblastoma survival
Patients with glioblastoma are wearing a cap that delivers electronic fields to treat their brain tumours
-
New gene therapy could have potential to treat recurrent glioblastomas
Researchers in collaboration with ZIOPHARM Oncology, a biopharmaceutical company announce positive updates on a Phase 1 clinical trials testing a new therapy
-
Ovarian cancer drug olaparib has the potential to treat glioblastoma
Researchers at Glasgow University have discovered that ovarian cancer drug, olaparib, has the potential to treat patients with glioblastomas
-
New glioblastoma and anaplastic astrocytoma book
Gideon Burrows has written his second book with personal stories, experiences, statistics and information, helped by a huge amount of people directly affected
-
Immunotherapy drug shows lack of promise in Phase 3 clinical trial for glioblastoma patients
Last week Bristol-Myers Squibb announced the initial results from their Phase 3 clinical trial that was assessing the effectiveness and safety of the immunotherapy drug Nivolumab in patients with recurrent glioblastoma.
-
Encouraging results for new clinical approach to glioblastoma treatments
Researchers at McGill University Health Centre (MUHC), Montreal have developed a new clinical approach to enhance the efficiency of treatment for glioblastomas, which increased the average survival time to 22 months.